PREVENE : Preemptive therapy with Venetoclax for high risk CLL stage A patients, a phase II trial of the FILO

Status

Not yet recruiting

Phases

Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-513718-37-00

Acronym

FILOCLL10-PREVENE

Enrollment

Registered

2024-08-01

Start date

Unknown

Completion date

Unknown

Last updated

2025-03-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

IGHV unmutated patients with high-risk stage A CLL features.

None listed

Sex/Gender

All

Age

18 Years to No maximum

France

None listed

Source: EU CTIS · Data processed: Feb 4, 2026